{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:41:34Z","timestamp":1790674894865,"version":"4.1.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T00:00:00Z","timestamp":1494028800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s11899-017-0382-1","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T00:45:21Z","timestamp":1494031521000},"page":"217-226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["A Review of Autologous Stem Cell Transplantation in Lymphoma"],"prefix":"10.1007","volume":"12","author":[{"given":"Umar","family":"Zahid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Amaraneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Husnain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyee","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irbaz Bin","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,6]]},"reference":[{"issue":"1","key":"382_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"382_CR2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342.","journal-title":"N Engl J Med"},{"issue":"23","key":"382_CR3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995;333(23):1540\u20135.","journal-title":"N Engl J Med"},{"issue":"9323","key":"382_CR4","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359(9323):2065\u201371.","journal-title":"Lancet"},{"issue":"12","key":"382_CR5","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.bbmt.2014.08.019","volume":"20","author":"PB Dahi","year":"2014","unstructured":"Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20(12):2004\u20139.","journal-title":"Biol Blood Marrow Transplant."},{"key":"382_CR6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12885-016-2311-4","volume":"16","author":"E Schorb","year":"2016","unstructured":"Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, et al. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma\u2014a randomized phase III trial (MATRix). BMC Cancer. 2016;16:282.","journal-title":"BMC Cancer"},{"issue":"12","key":"382_CR7","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1002\/cncr.23979","volume":"113","author":"N Arakelyan","year":"2008","unstructured":"Arakelyan N, Berthou C, Desablens B, de Guibert S, Delwail V, Moles MP, et al. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group. Cancer. 2008;113(12):3323\u201330.","journal-title":"Cancer"},{"issue":"12","key":"382_CR8","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1200\/JCO.2003.11.103","volume":"21","author":"M Federico","year":"2003","unstructured":"Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin\u2019s lymphoma responding to front-line therapy. J Clin Oncol. 2003;21(12):2320\u20135.","journal-title":"J Clin Oncol"},{"issue":"36","key":"382_CR9","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1200\/JCO.2007.15.5887","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Brice P, Ferme C, Divine M, Salles G, Bouabdallah R, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse\/refractory Hodgkin\u2019s lymphoma: results of the prospective multicenter H96 trial by the GELA\/SFGM study group. J Clin Oncol. 2008;26(36):5980\u20137.","journal-title":"J Clin Oncol"},{"issue":"25","key":"382_CR10","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"382_CR11","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2015.01.013","volume":"21","author":"A Beitinjaneh","year":"2015","unstructured":"Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, et al. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015;21(5):855\u20139.","journal-title":"Biol Blood Marrow Transplant."},{"key":"382_CR12","unstructured":"Columbia University. Autologous and allogeneic transplant for relapsed lymphoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[January 14."},{"issue":"4","key":"382_CR13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000449031","volume":"136","author":"S Yun","year":"2016","unstructured":"Yun S, Vincelette ND, Abraham I, Puvvada S, Anwer F. Outcome comparison of allogeneic versus autologous stem cell transplantation in transformed low-grade lymphoid malignancies: a systematic review and pooled analysis of comparative studies. Acta Haematol. 2016;136(4):244\u201355.","journal-title":"Acta Haematol"},{"key":"382_CR14","unstructured":"Fred Hutchinson Cancer Research Center. Autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in treatment patients with high-risk Hodgkin lymphoma N-HL, multiple myeloma, or chronic lymphocytic leukemia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[January 14, 2017]. Available from:."},{"issue":"7","key":"382_CR15","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.bbmt.2016.02.007","volume":"22","author":"JA Taverna","year":"2016","unstructured":"Taverna JA, Yun S, Jonnadula J, Saleh A, Riaz IB, Abraham I, et al. Role of maintenance therapy after high-dose chemotherapy and autologous hematopoietic cell transplantation in aggressive lymphomas: a systematic review. Biol Blood Marrow Transplant. 2016;22(7):1182\u201396.","journal-title":"Biol Blood Marrow Transplant."},{"key":"382_CR16","doi-asserted-by":"crossref","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016.","DOI":"10.3322\/caac.21357"},{"key":"382_CR17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","volume":"14","author":"R Camicia","year":"2015","unstructured":"Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer. 2015;14:207.","journal-title":"Mol Cancer"},{"issue":"12","key":"382_CR18","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116(12):2040\u20135.","journal-title":"Blood"},{"issue":"5","key":"382_CR19","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3324\/haematol.2011.056531","volume":"97","author":"WH Wilson","year":"2012","unstructured":"Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758\u201365.","journal-title":"Haematologica"},{"key":"382_CR20","unstructured":"Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB\/Alliance 50303. . ASH 58th Annual Meeting & Exposition; December 3\u20136, 2016; San Diego, CA, 2016."},{"issue":"18","key":"382_CR21","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","volume":"369","author":"PJ Stiff","year":"2013","unstructured":"Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 2013;369(18):1681\u201390.","journal-title":"N Engl J Med"},{"issue":"8","key":"382_CR22","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/sj.leu.2404781","volume":"21","author":"C Tarella","year":"2007","unstructured":"Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia. 2007;21(8):1802\u201311.","journal-title":"Leukemia"},{"issue":"9","key":"382_CR23","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3324\/haematol.2009.007005","volume":"94","author":"U Vitolo","year":"2009","unstructured":"Vitolo U, Chiappella A, Angelucci E, Rossi G, Liberati AM, Cabras MG, et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica. 2009;94(9):1250\u20138.","journal-title":"Haematologica"},{"issue":"9","key":"382_CR24","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00277-016-2729-4","volume":"95","author":"YR Kim","year":"2016","unstructured":"Kim YR, Kim SJ, Cheong JW, Yang DH, Lee H, Eom HS, et al. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. Ann Hematol. 2016;95(9):1491\u2013501.","journal-title":"Ann Hematol"},{"issue":"2","key":"382_CR25","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.4081\/hr.2015.5812","volume":"7","author":"H Kaneko","year":"2015","unstructured":"Kaneko H, Tsutsumi Y, Fujino T, Kuwahara S, Ohshiro M, Iwai T, et al. Favorable event free-survival of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for higher risk diffuse large B-cell lymphoma in first complete remission. Hematol Rep. 2015;7(2):5812.","journal-title":"Hematol Rep"},{"issue":"6","key":"382_CR26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.hoc.2016.07.002","volume":"30","author":"A Chiappella","year":"2016","unstructured":"Chiappella A, Castellino A, Vitolo U. State-of-the-art therapy for advanced-stage diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2016;30(6):1147\u201362.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"382_CR27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/2040620714547327","volume":"5","author":"W Iams","year":"2014","unstructured":"Iams W, Reddy NM. Consolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspective. Ther Adv Hematol. 2014;5(5):153\u201367.","journal-title":"Ther Adv Hematol"},{"issue":"27","key":"382_CR28","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184\u201390.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"382_CR29","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/annonc\/mdg702","volume":"14","author":"AD Zelenetz","year":"2003","unstructured":"Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol. 2003;14(Suppl 1):i5\u201310.","journal-title":"Ann Oncol"},{"issue":"10","key":"382_CR30","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","volume":"103","author":"T Kewalramani","year":"2004","unstructured":"Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103(10):3684\u20138.","journal-title":"Blood"},{"issue":"31","key":"382_CR31","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"\u2022 Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490\u20136. This randomized study including over 600 patients showed the salvage chemotherapy regimen GDP before ASCT to be non-inferior and had less toxicities compared to the standard DHAP regimen for R\/R DLBCL","journal-title":"J Clin Oncol"},{"issue":"8","key":"382_CR32","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","volume":"18","author":"T El Gnaoui","year":"2007","unstructured":"El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18(8):1363\u20138.","journal-title":"Ann Oncol"},{"issue":"31","key":"382_CR33","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","volume":"29","author":"C Thieblemont","year":"2011","unstructured":"Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, et al. The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29(31):4079\u201387.","journal-title":"J Clin Oncol"},{"issue":"2","key":"382_CR34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3960\/jslrt.56.100","volume":"56","author":"E Kondo","year":"2016","unstructured":"Kondo E. Autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma. J Clin Exp Hematop. 2016;56(2):100\u20138.","journal-title":"J Clin Exp Hematop"},{"issue":"6","key":"382_CR35","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"YB Chen","year":"2015","unstructured":"\u2022 Chen YB, Lane AA, Logan BR, Zhu X, Akpek G, Aljurf MD, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1046\u201353. Large study including almost 5000 patients from the CIBMTR database found patients undergoing HDT with ASCT who received high-dose CBV conditioning regimen had worse outcomes compared to other regimens","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"382_CR36","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"JM Vose","year":"2013","unstructured":"Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, et al. Phase III randomized study of rituximab\/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab\/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31(13):1662\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"382_CR37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/cam4.247","volume":"3","author":"S Auger-Quittet","year":"2014","unstructured":"Auger-Quittet S, Duny Y, Daures JP, Quittet P. Outcomes after (90) yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis. Cancer Med. 2014;3(4):927\u201338.","journal-title":"Cancer Med"},{"issue":"15","key":"382_CR38","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","volume":"124","author":"AM Petrich","year":"2014","unstructured":"Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354\u201361.","journal-title":"Blood"},{"key":"382_CR39","doi-asserted-by":"crossref","unstructured":"Landsburg DJ, et al. Benefit of consolidative autologous stem cell transplantation in first complete remission for patients with double hit lymphoma appears dependent on induction regimen intensity. (2016): 3455\u20133455.","DOI":"10.1182\/blood.V128.22.3455.3455"},{"issue":"7","key":"382_CR40","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677\u201384.","journal-title":"Blood"},{"issue":"22","key":"382_CR41","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood.V114.22.362.362","volume":"114","author":"E Hoster","year":"2009","unstructured":"Hoster E, Metzner B, Forstpointner R, Pfreundschuh M, Trumper L, Hallek M, et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood. 2009;114(22):362\u20133.","journal-title":"Blood"},{"issue":"10044","key":"382_CR42","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565\u201375.","journal-title":"Lancet"},{"issue":"3","key":"382_CR43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158(3):355\u201362.","journal-title":"Br J Haematol"},{"issue":"26","key":"382_CR44","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1200\/JCO.2005.05.016","volume":"23","author":"JM Connors","year":"2005","unstructured":"Connors JM. State-of-the-art therapeutics: Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23(26):6400\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"382_CR45","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ajh.24272","volume":"91","author":"SM Ansell","year":"2016","unstructured":"Ansell SM. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(4):434\u201342.","journal-title":"Am J Hematol"},{"key":"382_CR46","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1200\/JCO.1990.8.7.1173","volume":"8","author":"DJGJ Strauss","year":"1990","unstructured":"Strauss DJGJ, Myers J, Merke DP, Caravelli J, Chapman D, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin\u2019s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990;8:1173\u201386.","journal-title":"J Clin Oncol"},{"issue":"1","key":"382_CR47","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3324\/haematol.13484","volume":"94","author":"AM Carella","year":"2009","unstructured":"Carella AM, Bellei M, Brice P, Gisselbrecht C, Visani G, Colombat P, et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin\u2019s lymphoma responding to front-line therapy: long-term results. Haematologica. 2009;94(1):146\u20138.","journal-title":"Haematologica"},{"issue":"23","key":"382_CR48","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","volume":"116","author":"AJ Moskowitz","year":"2010","unstructured":"Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23):4934\u20137.","journal-title":"Blood"},{"issue":"3","key":"382_CR49","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.seminhematol.2016.05.010","volume":"53","author":"B Tresckow von","year":"2016","unstructured":"\u2022 von Tresckow B, Moskowitz CH. Treatment of relapsed and refractory Hodgkin lymphoma. Semin Hematol. 2016;53(3):180\u20135. Comprehensive review of current advancement in Hodgkin Lymphoma","journal-title":"Semin Hematol"},{"issue":"3","key":"382_CR50","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","volume":"97","author":"CH Moskowitz","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616\u201323.","journal-title":"Blood"},{"issue":"6","key":"382_CR51","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","volume":"18","author":"NL Bartlett","year":"2007","unstructured":"Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"382_CR52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","volume":"92","author":"A Santoro","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica. 2007;92(1):35\u201341.","journal-title":"Haematologica"},{"issue":"8852","key":"382_CR53","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051\u20134.","journal-title":"Lancet"},{"key":"382_CR54","first-page":"CD009411","volume":"6","author":"M Rancea","year":"2013","unstructured":"Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013;6:CD009411.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"382_CR55","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/sj.bmt.1701790","volume":"23","author":"DE Reece","year":"1999","unstructured":"Reece DE, Nevill TJ, Sayegh A, Spinelli JJ, Brockington DA, Barnett MJ, et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin\u2019s disease. Bone Marrow Transplant. 1999;23(11):1131\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"382_CR56","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bmt.1705951","volume":"41","author":"M Benekli","year":"2008","unstructured":"Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, et al. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2008;41(7):613\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"382_CR57","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.bbmt.2010.02.022","volume":"16","author":"S Arai","year":"2010","unstructured":"Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, et al. Phase I\/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2010;16(8):1145\u201354.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"382_CR58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/bjh.13803","volume":"172","author":"M Musso","year":"2016","unstructured":"Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, et al. Improved outcome of patients with relapsed\/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. Br J Haematol. 2016;172(1):111\u201321.","journal-title":"Br J Haematol"},{"issue":"4","key":"382_CR59","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3324\/haematol.2015.136408","volume":"101","author":"D Sibon","year":"2016","unstructured":"Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marcais A, et al. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA\/SFGM-TC study group. Haematologica. 2016;101(4):474\u201381.","journal-title":"Haematologica"},{"issue":"3","key":"382_CR60","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","volume":"16","author":"AJ Moskowitz","year":"2015","unstructured":"Moskowitz AJ, Schoder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284\u201392.","journal-title":"Lancet Oncol"},{"issue":"12","key":"382_CR61","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","volume":"21","author":"R Chen","year":"2015","unstructured":"Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, et al. Results of a multicenter phase II trial of Brentuximab Vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136\u201340.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"9980","key":"382_CR62","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853\u201362.","journal-title":"Lancet"},{"key":"382_CR63","doi-asserted-by":"crossref","unstructured":"Ansell SM. Nivolumab in the treatment of Hodgkin lymphoma. Clin Cancer Res. 2016.","DOI":"10.1158\/1078-0432.CCR-16-1387"},{"issue":"4","key":"382_CR64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139.","journal-title":"N Engl J Med"},{"key":"382_CR65","doi-asserted-by":"crossref","unstructured":"Moskowitz Cea. PD-1 blockade with the monoclonal antibody pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Preliminary results from a phase 1b study presented at the 56th meeting of the American Society for Hematology; December 2014; San Francisco, CA.","DOI":"10.1182\/blood.V124.21.290.290"},{"key":"382_CR66","doi-asserted-by":"crossref","unstructured":"Armand P TJ, et al. Nivolumab in patients (Pts) with relapsed or refractory classical Hodgkin lymphoma (R\/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039). . Blood 2015; 126(23): 583 [Oral and Poster Abstracts])","DOI":"10.1182\/blood.V126.23.583.583"},{"key":"382_CR67","doi-asserted-by":"crossref","unstructured":"Armand P SM, Ribrag V, et al. . PD-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: safety, efficacy, and biomarker assessment. Preliminary results presented at the 57th meeting of the American Society for Hematology; 2015; Orlando, FL.","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"382_CR68","doi-asserted-by":"crossref","unstructured":"Moskowitz CH, Zinzani PL, Fanale MA, Armand P, Johnson NA, Radford JA, et al. Pembrolizumab in relapsed\/refractory classical Hodgkin lymphoma: primary end point analysis of the phase 2 Keynote-087 Study. Blood. 2016;128(22).","DOI":"10.1002\/hon.2437_125"},{"key":"382_CR69","unstructured":"Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)\u2014a phase 2 study. Preliminary results presented at the meeting of the American Society for Clinical Oncology; June 2016; Chicago, IL."},{"key":"382_CR70","unstructured":"Chen RW ZP, Fanale MA et al. . Pembrolizumab for relapsed\/refractory classical Hodgkin lymphoma (R\/R cHL): phase 2 KEYNOTE-087 study. . 2016 ASCO Annual Meeting J Clin Oncol 34, (suppl; abstr 7555), 2016."},{"issue":"9","key":"382_CR71","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283\u201394.","journal-title":"Lancet Oncol."},{"key":"382_CR72","unstructured":"Hatake K KT, Fukuhara N et al. . Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): an interim analysis. . 2016 ASCO Annual Meeting J Clin Oncol 34, 2016 (suppl; abstr e19018), 2016."},{"issue":"1","key":"382_CR73","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminhematol.2013.11.001","volume":"51","author":"L Karlin","year":"2014","unstructured":"Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51(1):25\u201334.","journal-title":"Semin Hematol"},{"issue":"4","key":"382_CR74","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2011.08651.x","volume":"153","author":"CE Dearden","year":"2011","unstructured":"Dearden CE, Johnson R, Pettengell R, Devereux S, Cwynarski K, Whittaker S, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol. 2011;153(4):451\u201385.","journal-title":"Br J Haematol"},{"issue":"25","key":"382_CR75","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"3","key":"382_CR76","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2005.05478.x","volume":"129","author":"R Sonnen","year":"2005","unstructured":"Sonnen R, Schmidt WP, Muller-Hermelink HK, Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol. 2005;129(3):366\u201372.","journal-title":"Br J Haematol"},{"issue":"2","key":"382_CR77","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","volume":"151","author":"A Simon","year":"2010","unstructured":"Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151(2):159\u201366.","journal-title":"Br J Haematol"},{"key":"382_CR78","unstructured":"Delmer A, et al. . Intensified induction therapy with etoposide (VP16) and high-dose cytarabine (Ara-C) in patients aged less than 60 years with peripheral T cell\/NK lymphoma: preliminary results of the phase II GELA study LNH98T7. . in Proc Am Soc Clin Oncol 2003."},{"issue":"18","key":"382_CR79","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418\u201325.","journal-title":"Blood"},{"issue":"10","key":"382_CR80","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570\u20137.","journal-title":"Blood"},{"issue":"1","key":"382_CR81","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106\u201313.","journal-title":"J Clin Oncol"},{"issue":"9","key":"382_CR82","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","volume":"28","author":"P Corradini","year":"2014","unstructured":"\u2022 Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 2014;28(9):1885\u201391. A prospective trial studying the role of high dose chemo-immunotherapy with and without stem cell transplant in T cell Lymphoma","journal-title":"Leukemia"},{"issue":"1","key":"382_CR83","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bmt.2010.92","volume":"46","author":"I Choi","year":"2011","unstructured":"Choi I, Tanosaki R, Uike N, Utsunomiya A, Tomonaga M, Harada M, et al. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia\/lymphoma: results of prospective trials. Bone Marrow Transplant. 2011;46(1):116\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"382_CR84","doi-asserted-by":"crossref","first-page":"15","DOI":"10.17116\/terarkh201587715-25","volume":"87","author":"EN Parovichnikova","year":"2015","unstructured":"Parovichnikova EN, Kuz\u2019mina LA, Mendeleeva LP, Kliasova GA, Troitskaia VV, Sokolov AN, et al. Autologous hematopoietic stem cell transplantation as late high-dose consolidation in adult patients with T-cell lymphoblastic leukemias: results of a Russian multicenter study. Ter Arkh. 2015;87(7):15\u201325.","journal-title":"Ter Arkh"},{"key":"382_CR85","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.critrevonc.2015.12.016","volume":"99","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S. Panoptic clinical review of the current and future treatment of relapsed\/refractory T-cell lymphomas: peripheral T-cell lymphomas. Crit Rev Oncol Hematol. 2016;99:214\u201327.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"20","key":"382_CR86","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-10-1214","volume":"16","author":"SM Malik","year":"2010","unstructured":"Malik SM, Liu K, Qiang X, Sridhara R, Tang S, McGuinn Jr WD, et al. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2010;16(20):4921\u20137.","journal-title":"Clin Cancer Res"},{"key":"382_CR87","unstructured":"A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas. Clin Adv Hematol Oncol. 2014;12(2 Suppl 6):3\u20134."},{"key":"382_CR88","doi-asserted-by":"crossref","unstructured":"Makita S TK. Clinical features and current optimal management of natural killer\/T-cell lymphoma. Hematology\/Oncology Clinics of North America. 2017.","DOI":"10.1016\/j.hoc.2016.11.007"},{"key":"382_CR89","doi-asserted-by":"crossref","unstructured":"Yun S, Taverna JA, Puvvada SD, Anwer F. NK\/T-cell non-Hodgkin\u2019s lymphoma with secondary haemophagocytic lymphohistiocytosis treated with matched unrelated donor allogeneic stem cell transplant. BMJ Case Rep. 2014;2014.","DOI":"10.1136\/bcr-2014-205602"},{"issue":"12","key":"382_CR90","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","volume":"118","author":"G Visani","year":"2011","unstructured":"Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients. Blood. 2011;118(12):3419\u201325.","journal-title":"Blood"},{"issue":"2","key":"382_CR91","doi-asserted-by":"crossref","first-page":"163","DOI":"10.6002\/ect.2011.0092","volume":"10","author":"M Ramzi","year":"2012","unstructured":"Ramzi M, Mohamadian M, Vojdani R, Dehghani M, Nourani H, Zakerinia M, et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant. 2012;10(2):163\u20137.","journal-title":"Exp Clin Transplant"},{"issue":"3","key":"382_CR92","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10238-011-0157-2","volume":"12","author":"F Falzetti","year":"2012","unstructured":"Falzetti F, Di Ianni M, Ballanti S, Iodice G, Reale A, Minelli O, et al. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. Clin Exp Med. 2012;12(3):165\u201371.","journal-title":"Clin Exp Med"},{"key":"382_CR93","unstructured":"\u2022 Mounier N, Gill D, Linch D, Trneny M, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2016. Three independent factors (low to low-intermediate tIPI at relapse, progression > 6 months from ASCT, and chemosensitivities) predictive of improved outcomes were found using the famous CORAL cohort data for patients relapsed after autologous stem cell transplantation."}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-017-0382-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0382-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0382-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T22:02:27Z","timestamp":1602021747000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-017-0382-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,6]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["382"],"URL":"https:\/\/doi.org\/10.1007\/s11899-017-0382-1","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,6]]}}}